These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
404 related articles for article (PubMed ID: 38508081)
1. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment. Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081 [TBL] [Abstract][Full Text] [Related]
2. Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. Tachi T; Kijima N; Kuroda H; Ikeda S; Murakami K; Nakagawa T; Yaga M; Nakagawa K; Utsugi R; Hirayama R; Okita Y; Kagawa N; Kishima H; Imai C; Hosen N Cancer Immunol Immunother; 2024 Oct; 73(12):256. PubMed ID: 39367952 [TBL] [Abstract][Full Text] [Related]
3. IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma. Hou AJ; Shih RM; Uy BR; Shafer A; Chang ZL; Comin-Anduix B; Guemes M; Galic Z; Phyu S; Okada H; Grausam KB; Breunig JJ; Brown CE; Nathanson DA; Prins RM; Chen YY Neuro Oncol; 2024 Oct; 26(10):1850-1866. PubMed ID: 38982561 [TBL] [Abstract][Full Text] [Related]
4. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme. Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792 [TBL] [Abstract][Full Text] [Related]
5. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912 [TBL] [Abstract][Full Text] [Related]
6. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245 [TBL] [Abstract][Full Text] [Related]
7. CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia. Yang N; Zhang C; Zhang Y; Fan Y; Zhang J; Lin X; Guo T; Gu Y; Wu J; Gao J; Zhao X; He Z J Transl Med; 2024 Mar; 22(1):274. PubMed ID: 38475814 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer. Ohta K; Sakoda Y; Adachi K; Shinozaki T; Nakajima M; Yasuda H; Nagano H; Tamada K Cancer Res Commun; 2024 Sep; 4(9):2514-2524. PubMed ID: 39240078 [TBL] [Abstract][Full Text] [Related]
9. Enhancing Glioblastoma Immunotherapy with Integrated Chimeric Antigen Receptor T Cells through the Re-Education of Tumor-Associated Microglia and Macrophages. Zhu N; Chen S; Jin Y; Wang M; Fang L; Xue L; Hua D; Zhang Z; Jia M; Hao M; Zhang C ACS Nano; 2024 Apr; 18(17):11165-11182. PubMed ID: 38626338 [TBL] [Abstract][Full Text] [Related]
10. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma. Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525 [TBL] [Abstract][Full Text] [Related]
11. CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Guo S; Lei W; Jin X; Liu H; Wang JQ; Deng W; Qian W Blood Adv; 2024 Jun; 8(11):2635-2645. PubMed ID: 38564778 [TBL] [Abstract][Full Text] [Related]
12. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia. Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E Front Immunol; 2019; 10():3123. PubMed ID: 32117200 [TBL] [Abstract][Full Text] [Related]
13. RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma. Saleh HA; Mitwasi N; R Loureiro L; Kegler A; Soto KEG; Hoffmann L; Crespo E; Arndt C; Bergmann R; Bachmann M; Feldmann A Cancer Gene Ther; 2024 Sep; 31(9):1323-1334. PubMed ID: 38582787 [TBL] [Abstract][Full Text] [Related]
14. Expression of VISTA regulated via IFN-γ governs endogenous T-cell function and exhibits correlation with the efficacy of CD19 CAR-T cell treated B-malignant mice. Tang D; Zhao L; Yan F; Ren C; Xu K; Zhao K J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38925679 [TBL] [Abstract][Full Text] [Related]
15. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice. Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Immunomodulatory Effects of Radiation for Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme. Akhavan D; Subham S; Jeppson JD; Aguilar B; Wong RA; Hibbard JC; Hui S; Wong JYC; Forman SJ; Alizadeh D; Brown CE Cells; 2024 Jun; 13(13):. PubMed ID: 38994929 [TBL] [Abstract][Full Text] [Related]
17. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553 [TBL] [Abstract][Full Text] [Related]
18. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914 [TBL] [Abstract][Full Text] [Related]
19. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. Wang J; Toregrosa-Allen S; Elzey BD; Utturkar S; Lanman NA; Bernal-Crespo V; Behymer MM; Knipp GT; Yun Y; Veronesi MC; Sinn AL; Pollok KE; Brutkiewicz RR; Nevel KS; Matosevic S Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34740973 [TBL] [Abstract][Full Text] [Related]
20. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]